Adaptive Biotechnologies annual revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies Revenue Growth & History (ADPT)
Adaptive Biotechnologies reported $277.0M in revenue for fiscal 2025, an increase of 54.77% from the previous fiscal year.
View full Adaptive Biotechnologies company overviewAdaptive Biotechnologies annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $277.0M | $98.0M | +54.77% |
| 2024 | 2024-12-31 | $179.0M | $8.7M | +5.10% |
| 2023 | 2023-12-31 | $170.3M | −$15.0M | −8.11% |
| 2022 | 2022-12-31 | $185.3M | $31.0M | +20.06% |
| 2021 | 2021-12-31 | $154.3M | $56.0M | +56.88% |
| 2020 | 2020-12-31 | $98.4M | $13.3M | +15.65% |
| 2019 | 2019-12-31 | $85.1M | $29.4M | +52.83% |
| 2018 | 2018-12-31 | $55.7M | $17.2M | +44.77% |
| 2017 | 2017-12-31 | $38.4M | — | — |
Adaptive Biotechnologies quarterly revenue
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $71.6M | $12.7M | +21.53% |
| Q1 2026 | 2026-03-31 | $70.9M | $18.4M | +35.14% |
| Q4 2025 | 2025-12-31 | $71.7M | $24.2M | +51.04% |
| Q3 2025 | 2025-09-30 | $94.0M | $47.5M | +102.38% |
| Q2 2025 | 2025-06-30 | $58.9M | $15.7M | +36.33% |
| Q1 2025 | 2025-03-31 | $52.4M | $10.6M | +25.24% |
| Q4 2024 | 2024-12-31 | $47.5M | $1.7M | +3.66% |
| Q3 2024 | 2024-09-30 | $46.4M | $8.5M | +22.46% |
| Q2 2024 | 2024-06-30 | $43.2M | −$5.7M | −11.72% |
| Q1 2024 | 2024-03-31 | $41.9M | $4.2M | +11.23% |
| Q4 2023 | 2023-12-31 | $45.8M | −$9.4M | −17.05% |
| Q3 2023 | 2023-09-30 | $37.9M | −$9.9M | −20.72% |
| Q2 2023 | 2023-06-30 | $48.9M | $5.3M | +12.06% |
| Q1 2023 | 2023-03-31 | $37.6M | −$973,000 | −2.52% |
| Q4 2022 | 2022-12-31 | $55.2M | $17.3M | +45.53% |
| Q3 2022 | 2022-09-30 | $47.8M | $8.4M | +21.19% |
| Q2 2022 | 2022-06-30 | $43.7M | $5.2M | +13.39% |
| Q1 2022 | 2022-03-31 | $38.6M | $178,000 | +0.46% |
| Q4 2021 | 2021-12-31 | $37.9M | $7.7M | +25.66% |
| Q3 2021 | 2021-09-30 | $39.5M | $13.2M | +50.07% |
| Q2 2021 | 2021-06-30 | $38.5M | $17.5M | +83.46% |
| Q1 2021 | 2021-03-31 | $38.4M | $17.5M | +83.85% |
| Q4 2020 | 2020-12-31 | $30.2M | $6.0M | +24.69% |
| Q3 2020 | 2020-09-30 | $26.3M | $241,000 | +0.92% |
| Q2 2020 | 2020-06-30 | $21.0M | −$1.1M | −5.19% |
| Q1 2020 | 2020-03-31 | $20.9M | $8.2M | +65.09% |
| Q4 2019 | 2019-12-31 | $24.2M | — | — |
| Q3 2019 | 2019-09-30 | $26.1M | $8.9M | +51.61% |
| Q2 2019 | 2019-06-30 | $22.1M | $10.6M | +91.37% |
| Q1 2019 | 2019-03-31 | $12.7M | — | — |
| Q3 2018 | 2018-09-30 | $17.2M | — | — |
| Q2 2018 | 2018-06-30 | $11.6M | — | — |
Adaptive Biotechnologies revenue growth trends
Over the last five reported fiscal years, revenue grew from $98.4M to $277.0M, a compound annual growth rate of 23.00%. Adaptive Biotechnologies's latest reported quarter, Q2 2026, generated $71.6M in revenue, an increase of 21.53% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Adaptive Biotechnologies source filings ↗Community posts
Adaptive reports broader NCCN guidance for residual-disease testing
Adaptive ($ADPT) Biotechnologies said updated National Comprehensive Cancer Network guidance for multiple myeloma gives measurable residual disease testing a dedicated section and names clonoSEQ as a testing option. The update specifies a p ...
